Cefoperazone-Sulbactam and Coagulation

Introduction to Cefoperazone-Sulbactam and Coagulation

Cefoperazone-sulbactam can cause deranged INR values and increase the risk of bleeding, particularly in patients taking warfarin or with underlying coagulation disorders, and this effect is clinically significant, requiring monitoring and potential intervention 1

Cefoperazone-sulbactam affects coagulation through several mechanisms, including direct effect on coagulation factors, alteration of intestinal flora, and displacement of protein-bound warfarin, which can lead to increased risk of bleeding in patients on warfarin or with underlying coagulation disorders 1

Concomitant anticoagulant therapy, particularly warfarin, increases the risk of coagulation abnormalities when used with cefoperazone-sulbactam, as noted by the American Heart Association 1
Advanced age, renal impairment, malnutrition, liver disease, and long duration of therapy are also risk factors for coagulation abnormalities when using cefoperazone-sulbactam 1

The American Heart Association recommends monitoring coagulation parameters, including checking baseline INR before starting therapy and monitoring INR within 2-3 days of initiating therapy, particularly in patients on warfarin 2
Consideration of prophylactic vitamin K1 administration may prevent coagulation abnormalities, particularly important for patients on long-term anticoagulation or with other risk factors 2
For patients on warfarin, consideration of temporary warfarin dose reduction (25-33%) when initiating cefoperazone-sulbactam and monitoring INR more frequently during co-administration is recommended by the American College of Cardiology 1

Elevated INR increases the risk of spontaneous bleeding, and surgical considerations may require delaying procedures if INR is elevated, as noted by the American Heart Association 1
Anticoagulation management may require temporary adjustment of anticoagulant dosing when using cefoperazone-sulbactam, particularly in patients on warfarin 1